An interventional study of Stabilized 780±21 mV High-Oxidation-Potential Water in Oral Mucosal Pain, Oral Mucosal Irritation and TRPA1-Mediated Pain, sponsored by Dove Medical Press Ltd. Not yet recruiting at 1 site in China. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-19.
Sponsored by Dove Medical Press Ltd · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 247 studies in Pain with a site in China — 66 open to participants now, 72 under way, 2 of them phase 3. Pain · China.
Among the 247 studies in Pain with a site in China, this one is the 195th largest by planned enrollment of the 212 interventional ones that give a count, is one of 25 that started in 2026, is one of 117 with no phase, reaches primary completion later than 32 of the 71 other live ones, and was the 246th registered.
10,076 studies on the registry are indexed under Pain; 1,648 are open to participants now.
Browse Pain studies →66 of the 247 studies in Pain with a site in China are open now. Recruiting first, the newest first:
Yi Duan · Sites in China
Ages 18–75
Novartis Pharmaceuticals · Sites in China
Ages 18+
Yingyong Zhou,MD,PhD · Sites in China
Ages 18+
Haisco Pharmaceutical Group Co., Ltd. · Sites in China
Ages 18+
Lijiang Lv · Sites in China
Ages 18–60
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 928 Pain studies recruiting now, 384 (41%) set no upper age limit and 432 (47%) stop at 75 or younger; 145 take children under 18; 220 take healthy volunteers.
This study: 18 Years to 60 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
247 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 21 · Phase 2 27 · Phase 3 26 · Phase 4 30
First in 1992; this study’s year is marked. 25 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 24 is below the median of 66 across 8,512 interventional studies indexed under Pain.
Median enrollment 120 across the 212 interventional studies, 169 across the 34 observational. Of the 122 that completed or were terminated, 17 (14%) have results posted.
This tab as a report to print or save as PDF → With an account.
50 of 247 have an industry lead sponsor. The 10 most frequent:
Dove Medical Press Ltd is the lead sponsor of 12 studies on the registry; 1 is open to participants now.
Dove Medical Press Ltd has 1 study filed under Pain — fewer than ten, so there is no comparison to draw.
30 of the studies in Pain with a site in China that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07872826Phase 3The Third Xiangya Hospital of Central South UniversityA Clinical Trial Evaluating the Efficacy and Safety of Local Infiltration of RF16001 for Injection for Analgesia After Total Hip Arthroplasty in China | 2027-06-30 |
| NCT07533786Haisco Pharmaceutical Group Co., Ltd.A Clinical Trial Evaluating the Efficacy and Safety of HSK55718 in Patients for Postoperative Pain Treatment in Abdominal Surgery | 2026-11-22 |
| NCT06553495Jie ChenA Comparative Analysis of Intertransverse Nerve Block and Paravertebral Nerve Block in Endoscopic Hepatectomy | 2026-11-30 |
| NCT07947511Dove Medical Press LtdOral-Challenge Study: Steady-State High-ORP Water/Gel Relieves AITC- and Capsaicin-Induced Oral Pain in Healthy Volunteers | 2026-12-22 |
| NCT07557823Second Affiliated Hospital, School of Medicine, Zhejiang UniversityTranscutaneous Auricular Vagus Nerve Stimulation Combined With Cervical Epidural Injection for Cervical Radiculopathy | 2026-12-30 |
Add all 30 to your calendar (.ics) → With an account.
Among the 247 studies in Pain with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
To evaluate the efficacy and safety of stabilized 780±21 mV high-oxidation-potential water to rapidly relieve oral mucosal pain and irritation induced by AITC (wasabi-horseradish) and capsaicin (chili-oil), which activate TRPA1 and TRPV1 sensory ion-channels. Healthy volunteers receive oral 40 mL stabilized high-oxidation-potential water after oral irritant challenge. Pain-irritation NRS scores are assessed at baseline, 3 seconds, 30 seconds, 60 seconds, 120 seconds post-treatment. Safety observations are recorded throughout the study.
This is prospective, single-arm, open-label exploratory pilot study in healthy adult volunteers. Two separate oral irritant challenge models are applied: AITC-containing horseradish-wasabi challenge for TRPA1-mediated oral irritation-pain; capsaicin-containing chili-oil challenge for TRPV1-mediated burning oral pain. Total target enrollment is 24 healthy subjects (12 male,12 female). After irritant exposure, subjects take 40 mL stabilized 780±21 mV high-oxidation-potential water, hold in mouth then swallow. Subject-reported 0-10 NRS pain-irritation scores are collected at pre-challenge baseline; post-irritant baseline; 3 s,30 s,60 s,120 s after study product administration. Local oral-mucosal adverse reactions and systemic tolerability are monitored. Pre-existing rabbit ocular-surface safety testing supports mucosal safety of this formulation. This trial focuses on acute seconds-range symptom relief in experimental irritant-pain models.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Other: Stabilized 780±21 mV High-Oxidation-Potential Water
Intervention description: Stabilized electrolyzed saline water with oxidation-potential 780±21 mV. After oral irritant challenge (AITC-horseradish-wasabi or capsaicin-chili-oil), subject takes 40 mL of study liquid, holds in oral cavity briefly then swallow, single administration for each challenge test.
AITC-Induced Oral Pain-Irritation NRS Score
Participant self-reported 0-10 numerical rating scale for oral pain, stinging, choking-irritation triggered by AITC-containing horseradish-wasabi; 0 = no pain/irritation, 10 = worst imaginable oral irritation-pain.
Time frame: Post-irritant baseline, 3 seconds, 30 seconds post-product administration.
Capsaicin-Induced Oral Burning-Pain NRS Score
Participant self-reported 0-10 NRS for burning-pain triggered by capsaicin-containing chili-oil; 0 = no burning-pain,10 = worst imaginable burning-pain.
Time frame: Post-irritant baseline, 3 seconds, 30 seconds, 60 seconds,120 seconds post-product administration.
Participant Overall Subjective Relief Assessment Score
Subject-rated 0-10 scale for overall subjective relief of oral discomfort after each challenge test;0=no relief,10=complete relief.
Time frame: 120 seconds after product administration for each irritant challenge.
Incidence of Adverse Events
Incidence of product-related adverse events including oral mucosal stinging, numbness, gastrointestinal upset, throat irritation, nausea.
Time frame: Throughout entire study visit period (within 30 minutes of product exposure).
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Nov 2026; primary completion for Dec 2026, 1 month later.
Of 3,749 non-industry interventional studies with no phase under Pain, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 23. This study's planned 1 month is below that.
Counting every sponsor, half of 3,848 studies reached it within 10 months; a quarter within 4 and three quarters within 23.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Dove Medical Press Ltd